Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
71.20
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
565,914
Open
71.20
Bid (Size)
74.59 (14)
Ask (Size)
74.64 (3)
Prev. Close
71.20
Today's Range
71.20 - 71.20
52wk Range
60.47 - 76.56
Shares Outstanding
N/A
Dividend Yield
1.31%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Today 8:30 EDT
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
Today 7:53 EDT
AZN stock results show that AstraZeneca missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+4.09%
+4.09%
1 Month
+8.11%
+8.11%
3 Month
+6.91%
+6.91%
6 Month
+10.89%
+10.89%
1 Year
-5.91%
-5.91%
More News
Read More
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
Today 7:31 EDT
Via
Investor's Business Daily
Q1 2024 results
Today 2:00 EDT
From
AstraZeneca
Via
Business Wire
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
April 23, 2024
Via
InvestorPlace
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
April 23, 2024
Via
Chartmill
Looking At AstraZeneca's Recent Unusual Options Activity
April 19, 2024
Via
Benzinga
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Today 6:17 EDT
Via
Benzinga
European Stock: AstraZeneca
April 22, 2024
Via
Talk Markets
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
April 19, 2024
Via
Benzinga
Topics
Brexit
Exposures
Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
April 19, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
April 16, 2024
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
April 16, 2024
From
AstraZeneca
Via
Business Wire
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
April 14, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
April 12, 2024
Via
Benzinga
Exposures
Product Safety
Biotech Innovations Paving the Way in Breast Cancer Fight
April 11, 2024
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Product Safety
AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package Boost
April 11, 2024
Via
Benzinga
Exposures
Product Safety
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
April 11, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
Via
Benzinga
Exposures
Product Safety
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup
April 07, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
April 05, 2024
From
Daiichi Sankyo
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.